These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14968816)

  • 1. European Society of gene therapy-11th annual conference.
    Douglas JT
    IDrugs; 2004 Jan; 7(1):40-1. PubMed ID: 14968816
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe immunodeficiencies: bone marrow transplantation or gene therapy?
    Mariani SM
    MedGenMed; 2003 Jun; 5(2):19. PubMed ID: 14603118
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene therapy in man and mice: adenosine deaminase deficiency, ornithine transcarbamylase deficiency, and Duchenne muscular dystrophy.
    Grompe M; Mitani K; Lee CC; Jones SN; Caskey CT
    Adv Exp Med Biol; 1991; 309B():51-6. PubMed ID: 1781405
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene therapy progress and prospects: gene therapy for severe combined immunodeficiency.
    Gaspar HB; Howe S; Thrasher AJ
    Gene Ther; 2003 Nov; 10(24):1999-2004. PubMed ID: 14566358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine deaminase deficiency: a model system for human somatic cell gene correction therapy.
    Vega MA
    Biochim Biophys Acta; 1992 Apr; 1138(4):253-60. PubMed ID: 1562612
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells.
    Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D
    Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454
    [No Abstract]   [Full Text] [Related]  

  • 7. Adenosine deaminase gene therapy protocol revisited.
    Kohn DB
    Mol Ther; 2002 Feb; 5(2):96-7. PubMed ID: 11829515
    [No Abstract]   [Full Text] [Related]  

  • 8. The Journal of Gene Medicine Japanese Society of Gene Therapy Young Investigator Award from 2010.
    J Gene Med; 2011 Nov; 13(11):644-5. PubMed ID: 22125101
    [No Abstract]   [Full Text] [Related]  

  • 9. EMA greenlights second gene therapy.
    Mullard A
    Nat Rev Drug Discov; 2016 May; 15(5):299. PubMed ID: 27139988
    [No Abstract]   [Full Text] [Related]  

  • 10. ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.
    Ylä-Herttuala S
    Mol Ther; 2016 Jun; 24(6):1013-1014. PubMed ID: 27324442
    [No Abstract]   [Full Text] [Related]  

  • 11. Gene therapy for human severe combined immunodeficiencies.
    Fischer A; Hacein-Bey S; Le Deist F; de Saint Basile G; Cavazzana-Calvo M
    Immunity; 2001 Jul; 15(1):1-4. PubMed ID: 11485732
    [No Abstract]   [Full Text] [Related]  

  • 12. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.
    Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV
    Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
    Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
    Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.
    Schimmer J; Breazzano S
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):57-61. PubMed ID: 27267267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy's out-of-body experience.
    Scott CT; DeFrancesco L
    Nat Biotechnol; 2016 Jun; 34(6):600-7. PubMed ID: 27281416
    [No Abstract]   [Full Text] [Related]  

  • 16. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene.
    Dunbar C; Chang L; Mullen C; Ramsey WJ; Carter C; Kohn D; Parkman R; Lenarsky C; Weinberg K; Wara D; Culver KW; Anderson WF; Leitman S; Fleisher T; Klein H; Shearer G; Clerici M; McGarrity G; Bastian J; Hershfield MS
    Hum Gene Ther; 1999 Feb; 10(3):477-88. PubMed ID: 10048399
    [No Abstract]   [Full Text] [Related]  

  • 17. Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.
    Silver JN; Flotte TR
    Pharmacogenomics; 2008 Jul; 9(7):947-68. PubMed ID: 18597656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recollections from a Pioneer Who Provided the Foundation for the Success of Gene Therapy in Treating Severe Combined Immune Deficiencies.
    Wilson JM
    Hum Gene Ther Clin Dev; 2016 Jun; 27(2):53-6. PubMed ID: 27314911
    [No Abstract]   [Full Text] [Related]  

  • 19. Gene therapy for ADA-SCID, the first marketing approval of an
    Aiuti A; Roncarolo MG; Naldini L
    EMBO Mol Med; 2017 Jun; 9(6):737-740. PubMed ID: 28396566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy: great expectations?
    Thrasher AJ
    Med J Aust; 2005 May; 182(9):440-1. PubMed ID: 15865584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.